Floatz logo

Dynastat

Sickle-Cell Disease with Crisis

Oman Medical Speciality BoardPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

134 Active assets in the Sickle-Cell Disease with Crisis cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Dynastat is also rated in:

Perioperative CareDormant
BB
Indicative ·
69 / 100
View asset →
Chronic Post-operative PainDormant
BB
Indicative ·
69 / 100
View asset →
complex regional pain syndrome type 2Dormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →